Evaluating transportability of in-vitro cellular models to in-vivo human phenotypes using gene perturbation data
Authors:
- Laurence J HoweLHLaurence J Howe
- George Davey SmithGSGeorge Davey Smith
- Neil M DaviesNDNeil M Davies
- Jorge Esparza-GordilloJEJorge Esparza-Gordillo
- Jimmy Z LiuJLJimmy Z Liu
- Ashwini SharmaASAshwini Sharma
Preprint
Abstract
Gene perturbation screens (e.g. CRISPR-Cas9) assess the impact of gene disruption on in-vitro cellular phenotypes (e.g., proliferation, anti-viral response, transcriptomics). In-vitro experiments can be useful models for understanding the aetiology of in-vivo (organismal) phenotypes. For example, anti-viral response in immune cells and infectious disease outcomes. However, assessing whether an in-vitro cellular model is effectively capturing in-vivo biology is challenging. An in-vitro model is ‘transportable’ to an in-vivo phenotype of interest if perturbations impacting the in-vitro phenotype also impact the in-vivo phenotype with mechanism-consistent directionality and effect sizes. We propose a framework; Gene Perturbation Analysis for Transportability (GPAT), to assess model transportability using gene perturbation effect estimates from perturbation screens ( in-vitro cellular phenotypes) and loss-of-function burden tests ( in-vivo phenotypes). Using UK Biobank whole-genome sequence data and data from published genome-wide CRISPR-Cas9 screens, we evaluated transportability of in-vitro cellular models to in-vivo human phenotypes. In hypothesis-driven analyses, we found evidence that higher lysosomal cholesterol accumulation in-vitro is a transportable model for lower LDL-cholesterol measured in human blood plasma (P = 0.0006), consistent with the known role of lysosomes in lipid biosynthesis. In contrast, we found limited evidence for other putative in-vitro models. In hypothesis-free analyses, we found strong evidence for transportability of proliferation in cancer cell lines for in-vivo human plasma cellular phenotypes. For example, higher proliferation in an erythroleukemia cell line and lower plasma lymphocyte percentage. GPAT enables systematic evaluation of the transportability of in-vitro cellular models to in-vivo phenotypes, informing assay prioritization and supporting novel hypothesis generation.Keywords
All Related Versions
- Published version: Nature Communications, 17 (1).
This publication has 39 references indexed in Scilit:
- Evidence triangulation in health researchEuropean Journal of Epidemiology, 2025
- Genome-wide CRISPR screening of chondrocyte maturation newly implicates genes in skeletal growth and height-associated GWAS lociCell Genomics, 2023
- Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistenceCancer Cell, 2022
- Genome wide CRISPR screening reveals a role for sialylation in the tumorigenesis and chemoresistance of acute myeloid leukemia cellsCancer Letters, 2021
- Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 InfectionCell, 2021
- Functional Genomics for Cancer Drug Target DiscoveryCancer Cell, 2020
- Emerging Roles for the Lysosome in Lipid MetabolismTrends in Cell Biology, 2017
- Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median EstimatorGenetic Epidemiology, 2016
- Rare-Variant Association Analysis: Study Designs and Statistical TestsThe American Journal of Human Genetics, 2014
- Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart DiseaseJACC, 2012